A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples